---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-003041"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T13:27:54.969809+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Corvus reports Q1 net loss of $7.9M; CPI-818 shows 6/13 ORR in ALC>900 TCL patients

## Summary
- Net loss of $7.9M vs $8.3M in Q1 2022; cash & securities $34.5M as of March 31, 2023.
- CPI-818 Phase 1/1b TCL: 2 CR, 1 nodal CR, 3 PR among 19 evaluable; 9 patients remain on therapy.
- ALC>900 biomarker selected 6/13 ORR; median PFS 19.9 months for ALC>900 vs 2.1 months for <900.
- CFO expects FY2023 net cash use of $19-22M; projected year-end cash of $20-23M funding into 2024.
- Plans to meet with FDA in Q3 2023 to discuss potential registrational Phase 3 trial for CPI-818.

## SEC filing metadata
- accession: 0001171843-23-003041
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184323003041/0001171843-23-003041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184323003041/f8k_050823.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-003041
- JSON: https://secwatch.observer/filing/0001171843-23-003041.json
- Plain text: https://secwatch.observer/filing/0001171843-23-003041.txt

## Key facts
- Earnings Releases
  Corvus Pharmaceuticals, Inc. reported the three months ended March 31, 2023 results: net income $7.9 million.
  - Period: the three months ended March 31, 2023
  - Net income: $7.9 million
  - Result: reported results
  source text: The net loss for the three months ended March 31, 2023 was $7.9 million compared to a net loss of $8.3 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626971/000117184323003041/0001171843-23-003041-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.